Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy.

DISCLOSURES: Dr Taddei-Allen was a PRIME Education Moderator on Hypertrophic Cardiomyopathy CE at AMCP Nexus 2021; AJMC article on managed care considerations for hypertrophic cardiomyopathy. No funding was contributed toward the writing of this commentary.